<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010425</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-001 (Prot. 3695)</org_study_id>
    <nct_id>NCT01010425</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)</brief_title>
  <official_title>Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascendis Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascendis Pharma A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo and active controlled dose-ascending study to investigate
      safety, tolerability, pharmacokinetics and pharmacodynamics of ACP-001 (TransCon PEG hGH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability (adverse events, local reactions, immunogenicity)</measure>
    <time_frame>0-42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics; AUC and Cmax for hGH, TransCon-PEG hGH; and Pharmacodynamics measured by IGF-1 and IFG-BP</measure>
    <time_frame>0-28 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ACP-001, dose-level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ACP-001, dose-level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ACP-001, dose-level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ACP-001, dose-level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-001 (TransCon PEG hGH)</intervention_name>
    <description>ACP-001, dose-level 1, s.c., single-dose</description>
    <arm_group_label>ACP-001, dose-level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-001 (TransCon PEG hGH)</intervention_name>
    <description>ACP-001, dose-level 2, s.c., single-dose</description>
    <arm_group_label>ACP-001, dose-level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-001 (TransCon PEG hGH)</intervention_name>
    <description>ACP-001, dose-level 3, s.c., single-dose</description>
    <arm_group_label>ACP-001, dose-level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-001 (TransCon PEG hGH)</intervention_name>
    <description>ACP-001, dose-level 4, s.c., single-dose</description>
    <arm_group_label>ACP-001, dose-level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, s.c., single-dose</description>
    <arm_group_label>ACP-001, dose-level 1</arm_group_label>
    <arm_group_label>ACP-001, dose-level 2</arm_group_label>
    <arm_group_label>ACP-001, dose-level 3</arm_group_label>
    <arm_group_label>ACP-001, dose-level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Growth Hormone</intervention_name>
    <description>Human Growth Hormone, s.c., daily for 7 days</description>
    <arm_group_label>ACP-001, dose-level 1</arm_group_label>
    <arm_group_label>ACP-001, dose-level 2</arm_group_label>
    <arm_group_label>ACP-001, dose-level 3</arm_group_label>
    <arm_group_label>ACP-001, dose-level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  20 to 45 years old

          -  Body Mass Index of 18.5 kg/m2 and less than or equal to 29.9 kg/m2

          -  Others

        Exclusion Criteria:

          -  Known history of hypersensitivity to human growth hormone (hGH)

          -  Known history of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal,
             neurological, hematological, immunological, hepatic or renal disease, or malignancies

          -  Others
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ascendis Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Ascendis Pharma A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <last_update_submitted>June 7, 2010</last_update_submitted>
  <last_update_submitted_qc>June 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Ascendis Pharma A/S</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

